Demant Operating Income 2012-2024 | WILYY

Demant operating income for the twelve months ending December 31, 2024 was $0M, a 0% increase year-over-year.

  • Demant annual operating income for 2024 was $0.657B, a 9.01% increase from 2023.
  • Demant annual operating income for 2023 was $0.602B, a 32.63% increase from 2022.
  • Demant annual operating income for 2022 was $0.454B, a 17.15% decline from 2021.

Demant Operating Income 2012-2024 | WILYY

  • Demant annual operating income for 2024 was $0.657B, a 9.01% increase from 2023.
  • Demant annual operating income for 2023 was $0.602B, a 32.63% increase from 2022.
  • Demant annual operating income for 2022 was $0.454B, a 17.15% decline from 2021.
Related Stocks
Company NameMarket
Cap
Abbott Laboratories (ABT)$229.2B
Boston Scientific (BSX)$152.7B
Stryker (SYK)$149.2B
EssilorLuxottica (ESLOY)$131.9B
Medtronic (MDT)$115.1B
Lonza Group Ag (LZAGY)$50.1B
Haleon (HLN)$43.5B
ResMed (RMD)$37.3B
GE HealthCare Technologies (GEHC)$34.5B
Agilent Technologies (A)$32.2B
Terumo (TRUMY)$24.4B
Koninklijke Philips (PHG)$23.5B
Insulet (PODD)$20.3B
Zimmer Biomet Holdings (ZBH)$18.6B
Baxter (BAX)$14.6B
Smith & Nephew SNATS (SNN)$13B
Sunny Optical Technology (SNPTF)$10.4B
Bio-Rad Laboratories (BIO)$6.7B
Lantheus Holdings (LNTH)$5.1B
Perrigo (PRGO)$3.7B
Prestige Consumer Healthcare (PBH)$3.7B
Haemonetics (HAE)$3.6B
Shandong Weigao Medical Polymer (SHWGF)$3.5B
Envista Holdings (NVST)$3.3B
ICU Medical (ICUI)$3.1B
LeMaitre Vascular (LMAT)$1.9B
QuidelOrtho (QDEL)$1.9B
AtriCure (ATRC)$1.5B
Acuren (TIC)$1.4B
Phibro Animal Health (PAHC)$1.2B